The National Blood Authority is standardising and strengthening access criteria for immunoglobulin (Ig) funded by all Australian governments under the national blood arrangements.
The 'Criteria for the Clinical Use of Intravenous Immunoglobulin in Australia' (the Criteria) was first published in 2007 and updated in 2012. After an independent review of the governance and access arrangements, the National Blood Authority (NBA) established a network of governance committees including specialist working groups (SWGs) and developed an online authorisation system (BloodSTAR). The Criteria currently included in BloodSTAR reflects the 2012 second edition of the Criteria. All states and territories, with the exception of NSW, now use BloodSTAR.
The SWGs reviewed the evidence and made revisions for V3 of the Criteria. In 2015, public consultation was held on proposed V3 changes for conditions where Ig has an Established or Emerging Therapeutic Role. In 2017, public consultation was held on proposed V3 changes for conditions listed for Use in Exceptional Circumstances Only and for indications where Ig use is Not Supported.
The V3 changes were endorsed by the National Immunoglobulin Governance Advisory Committee prior to presentation to the Jurisdictional Blood Committee for approval.
The proposed changes, which aim to more clearly articulate and standardise the diagnostic, qualifying and review criteria, are required to assist with managing the growth in demand for this precious, human-derived product by ensuring it is only used for clinically appropriate purposes. The revised Criteria will ensure strengthened qualifying and review criteria, initial and continuing authorisation periods', dosing controls and ensure the submission of supporting evidence.
The V3 Criteria will undergo an extensive process to upload into Blood-STAR and transition existing patients to the new criteria. Background: Ruxolitinib is an oral tablet and is an inhibitor for Janus Associated Kinases (JAKs) JAK1 and JAK2. It is approved in Australia for the treatment of myelofibrosis. STAT1 GOF mutation was reported as a cause of autosomal dominant chronic mucocutaneous candidiasis (CMC) in 2011. Recent case reports with ruxolitinib have reported clinical benefit in alopecia areata and STAT1 GOF chronic mucocutaneous candidiasis.
P78 RUXOLITINIB USE IN A CHILD WITH CHRONIC MUCOCUTANEOUS CANDIDIASIS AND AUTOSOMAL DOMINANT SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION 1 GAIN OF FUNCTION (STAT1 GOF) MUTATION
Case report: We report our clinical experience in a 4-year-old child who is part of a large kindred affected by autosomal dominant CMC. She presented with onychomycosis, mild oral candida, and a large chronic ulcer of scalp. Scalp fungal scrapings grew aspergillus ornatus a soil fungus, and Lictheimia corymbifera. Fungal hyphae were seen on direct microscopy. Staphlococcus aureas and mixed growth including pseudomonas was also found.
Although we suspected autosomal dominant STAT1 GOF in distant family members they did not have a genetic diagnosis established. We performed Sanger sequencing on the index patient and detected a pathologic variant in STAT1 gene consistent with the diagnosis of STAT1 GOF.
Scalp debridement, standard antimicrobial therapy and antifungal therapy was implemented to treat the scalp ulcer. Given the severity of the disease, and lack of response, Ruxolitinib 5 mg nocte was added in as an adjuvant. Dosage was increased to 10 mg after one month. After 6 weeks of therapy significant improvement has been noted with hair regrowth, loss of hyperkeratotic crusting, and early skin regeneration. No significant side effects were noted. Case report: Our index case is a 2-year-old Indigenous female patient, referred with recurrent 'severe infected eczema,' requiring multiple admissions. Consideration had been given to STAT3 mutation, however, extensive workup, including immunological workup, lead to the diagnosis of HTLV-1 on blood PCR. Furthermore, she fulfilled the major criteria for the diagnosis of infective dermatitis associated with HTLV-1. Since diagnosis, when compliant with appropriate treatment, response has been dramatic.
Diagnosis: HTLV-1 infection is diagnosed on blood PCR. Prognostically, an HTLV-1c proviral load is essential.
In addition to a blood PCR, clinical criteria for diagnosis of infective dermatitis associated with HTLV-1 requires presence of skin lesions and chronic relapsing dermatitis recurring post cessation of systemic treatment, with or without crusting of nostrils.
Treatment: Treatment is aimed at controlling the complicating infections of staphylococcus aureus and beta haemolytic streptococcus. Long-term trimethoprim/sulfamethoxazole is recommended until at least adolescence.
Conclusion:
Infective dermatitis associated with HTLV-1 is a clinically important mimic of other childhood dermatoses which requires high index of suspicion to ensure aggressive long term treatment to reduce morbidity and mortality. 
